Interestingly, the role of CDKN2A/B alterations in CCA is consistent with those found in other onco-hematologic settings, such as acute lymphoblastic leukemia, where CDKN2A/B mutations have been highlighted as independent poor prognostic markers and then included in the risk stratification26. This evidence concerns the gene CDKN2A and cholangiocarcinoma.